An interventional study of Transorbital electrical stimulation (Eyetronic Next Wave 1.1) and Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation in Multiple Sclerosis and Optic Neuritis, sponsored by Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts. Completed at 2 sites in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 376 studies in Multiple Sclerosis with a site in France — 63 open to participants now, 92 under way, 18 of them phase 3. Multiple Sclerosis · France.
Among the 376 studies in Multiple Sclerosis with a site in France, this one is the 192nd largest by enrollment of the 244 interventional ones that give a count, is one of 29 that started in 2019, is one of 110 with no phase, and was the 215th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →63 of the 376 studies in Multiple Sclerosis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Lille · Sites in France
Ages 18–65
University Hospital, Montpellier · Sites in France
Ages 40+
University Hospital, Caen · Sites in France
Ages 18+
Otto Bock France SNC · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
376 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 28 · Phase 3 77 · Phase 4 25
First in 1999; this study’s year is marked. 29 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is close to the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 144 across the 244 interventional studies, 174 across the 132 observational. Of the 255 that completed or were terminated, 69 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 376 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts is the lead sponsor of 28 studies on the registry; 16 are open to participants now.
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts has 1 study filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
18 of the studies in Multiple Sclerosis with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT03653273Phase 3Rennes University HospitalDisease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP) | 2027-07 |
| NCT05519553Nantes University HospitalPeer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis | 2026-12-01 |
| NCT07108088ÖSSUR FranceEvaluation of the NEUROSWING Orthosis on Walking Speed in a Population With Dorsal and/or Plantar Flexor Deficits, With a View to a Reimbursement Application | 2026-12-31 |
| NCT05772637Assistance Publique - Hôpitaux de ParisClinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis | 2027-02-14 |
Add all 18 to your calendar (.ics) → With an account.
Among the 376 studies in Multiple Sclerosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In light of experimental models showing that neuronal electrical activity is crucial for the remyelination process, we hypothesize that maintenance of electrical axonal activity in the early stages of optic neuritis may promote myelin repair, limiting thereby axonal degeneration.
In humans, electrical stimulation of the optic nerve has been tested mainly in ischemic neuropathy and retinitis pigmentosa, which are both associated with severe axonal/retinal pathology and poor visual prognosis. In contrast, the inflammation of the optic nerve in optic neuritis is generally transient, with less severe axonal damage at the acute phase, which would allow for better efficacy of electrical stimulation as a strategy to promote remyelination and neuroprotection.In light of experimental models showing that neuronal electrical activity is crucial for the remyelination process, we hypothesize that maintenance of electrical axonal activity in the early stages of optic neuritis may promote myelin repair, limiting thereby axonal degeneration.
This is a randomized, controlled, prospective, interventional, blinded trial which aims to evaluate the safety and efficacy of transorbital electrical nerve stimulation on remyelination and neuroprotection after an acute episode of retrobulbar optic neuritis in patients with multiple sclerosis (MS).
Expected Explorations: The study is composed of 14 visits: a screening/inclusion visit with neurological and ophthalmological evaluation, electrophysiology, MRI and Magnetoencephalography (MEG), 10 transorbital electrical stimulation or sham stimulation visits and finally 3 follow-up visits and evaluations (neurological and ophthalmological). Patient's participation will last 49 weeks (inclusion visit and 48 weeks of follow-up). Participation of healthy volunteers will last one day.
MS patients diagnosed with an optic neuritis will be randomized either in the active arm (transorbital electrical stimulation of the optic nerve - 10 sessions during 2 consecutive weeks) or in the placebo arm (sham stimulation - 10 sessions during 2 consecutive weeks) Expected benefits: Electrical stimulation of the optic nerve after an acute episode of retrobulbar optic neuritis may promote remyelination in the optic nerve and a better long-term visual outcome.
The criteria were revised on the registry on Nov 17, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Healthy Volunteers:
Exclusion Criteria:
For patients:
Differential diagnosis of Optic neuritis:
i) Atypical acute optic neuritis (papillitis, severe papilledema, initial optic atrophy) ii) Optic neuromyelitis iii) Normal VEP during the inclusion visit iv) No detection of VEP during the inclusion visit
Pacemaker or neurosensory stimulator or implantable defibrillator Clip on an aneurysm or clip on a vascular malformation of the brain Cochlear implants Ocular or cerebral ferromagnetic foreign bodies Metal prostheses or metal clips or splinters Ventriculoperitoneal neurosurgical bypass valves Permanent makeup of the eyelids or lips Black tattoo, important and close to the cranio-facial sphere. Copper Intrauterine Device Person with proven claustrophobia Epilepsy Brain tumor Intraocular pressure without specific treatment Hypertension without treatment Acute retinal hemorrhage Periorbital skin irritation Significant cognitive deficit Known gadolinium allergy
For healthy volunteers:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transorbital electrical stimulation of the optic nerve - 10 sessions during 2 consecutive weeks
Device: Transorbital electrical stimulation (Eyetronic Next Wave 1.1)
Sham stimulation - 10 sessions during 2 consecutive weeks
Device: Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation
Calibration phase: The patient will use a response button to indicate the threshold from which he feels a luminous sensation (phosphene). In a second step, he will use the same answer button to indicate the stimulation frequency from which the phosphenes become continuous. Stimulation phase: From these 2 parameters (amplitude and frequency), the stimulation session will begin for a duration of approximately 40 to 50 minutes, the settings being dependent of the individual thresholds.
The calibration phase is identical to the active stimulation. During the stimulation phase, the operator will not start the stimulation session.
P100 latency (VEP) after treatment
Modification of the latency of P100 wave measured by Visual Evoked Potential (VEP) after 24 weeks of treatment with electrical or sham stimulation.
Time frame: 24 weeks
Change of P100 amplitude (VEP) after treatment
Modification of the amplitude of P100 wave measured by Visual Evoked Potential (VEP) after 24 weeks of treatment with electrical or sham stimulation.
Time frame: 24 weeks
Change of P100 latency and amplitude (VEP) after treatment
Modification of the latency and amplitude of P100 wave measured by Visual Evoked Potential (VEP) after 12 and 48 weeks of treatment with electrical or sham stimulation.
Time frame: 12 and 48 weeks
Evolution of macular volume after treatment
Evolution since inclusion of macular volume (with Optical Coherence Tomography) at weeks 12, 24 and 48 after transorbital electrical treatment or sham stimulation.
Time frame: 12, 24 and 48 weeks
Change of mean and temporal Retinal Nerve Fiber Layer (RNFL) thickness and average thickness of macular ganglion cell layer after treatment
Evolution since inclusion of mean and temporal Retinal Nerve Fiber Layer (RNFL) thickness and average thickness of macular ganglion cell layer (with Optical Coherence Tomography) at weeks 12, 24 and 48 after transorbital electrical treatment or sham stimulation.
Time frame: 12, 24 and 48 weeks
Change of average thickness of macular ganglion cell layer after treatment
Evolution since inclusion of average thickness of macular ganglion cell layer (with Optical Coherence Tomography) at weeks 12, 24 and 48 after transorbital electrical treatment or sham stimulation.
Time frame: 12, 24 and 48 weeks
Change of mean deflection of visual field 24-2 after treatment
Change in the mean deflection of visual field 24-2 (24-2 Humphrey visual field analyser) at weeks 12, 24 and 48 compared to inclusion after electrical treatment or sham stimulation.
Time frame: 12, 24 and 48 weeks
Occurrence of adverse events related or not to the stimulation
Reporting of adverse events related or not to the stimulation
Time frame: through study completion, an average of 3 years
Ran from Aug 2019 to primary completion in Feb 2023, 42 months.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 42 months is above that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Jul 2019 → Aug 2019, primary completion Jul 2021 → Feb 2023 and completion Jul 2022 → Jul 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts